ReviewAdvances in pharmacology (San Diego, Calif.)2020
Neurobiological biomarkers of response to ketamine.
Review in Advances in pharmacology (San Diego, Calif.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- How Do People Who Undergo Ketamine Treatment for a Psychiatric Problem Subjectively Experience This Intervention? A Meta-Synthesis of Qualitative Studies.International journal of mental health nursing · 2025Pooled it
- Exploring the link between waking gamma and sleep delta power in healthy volunteers and individuals with treatment-resistant depression.Journal of affective disorders · 2025Trial
- Functional changes in sleep-related arousal after ketamine administration in individuals with treatment-resistant depression.Translational psychiatry · 2024Trial
- Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Interest-activity symptom severity predicts response to ketamine infusion in treatment-resistant depression.Psychopharmacology · 2021Trial
- Ketamine persists within neuronal compartments long after systemic clearance.Research square · 2026Article
- Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.Focus (American Psychiatric Publishing) · 2025Article
- Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms.Biomedicines · 2024Review
- Review
- Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression.Translational psychiatry · 2024Article
- Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer's Disease Progression.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Predicting treatment response to ketamine in treatment-resistant depression using auditory mismatch negativity: Study protocol.PloS one · 2024Article
- Suicide prevention and ketamine: insights from computational modeling.Frontiers in psychiatry · 2023Review
- Predicting Antidepressant Effects of Ketamine: the Role of the Pregenual Anterior Cingulate Cortex as a Multimodal Neuroimaging Biomarker.The international journal of neuropsychopharmacology · 2022Article
- The Roles of Imaging Biomarkers in the Management of Chronic Neuropathic Pain.International journal of molecular sciences · 2022Review
- Ketamine treatment for depression: a review.Discover mental health · 2022Review
- Glutamate modulators and beyond: A neuroscience revolution in the making.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2022Article
- Key considerations in the pharmacological management of treatment-resistant depression.Expert opinion on pharmacotherapy · 2021Article
- Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
As a field, psychiatry is undergoing an exciting paradigm shift toward early identification and intervention that will likely minimize both the burden associated with severe mental illnesses as well as their duration. In this context, the rapid-acting antidepressant ketamine has revolutionized our understanding of antidepressant response and greatly expanded the pharmacologic armamentarium for treatment-resistant depression. Efforts to characterize biomarkers of ketamine response support a growing emphasis on early identification, which would allow clinicians to identify biologically enriched subgroups with treatment-resistant depression who are more likely to benefit from ketamine therapy. This chapter presents a broad overview of a range of translational biomarkers, including those drawn from imaging and electrophysiological studies, sleep and circadian rhythms, and HPA axis/endocrine function as well as metabolic, immune, (epi)genetic, and neurotrophic biomarkers related to ketamine response. Ketamine's unique, rapid-acting properties may serve as a model to explore a whole new class of novel rapid-acting treatments with the potential to revolutionize drug development and discovery. However, it should be noted that although several of the biomarkers reviewed here provide promising insights into ketamine's mechanism of action, most studies have focused on acute rather than longer-term antidepressant effects and, at present, none of the biomarkers are ready for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.